Study of Omalizumab in Moderate to Severe Bronchial Asthma
Study of Omalizumab in Moderate to Severe Bronchial Asthma
This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply